🔴 Scholar Rock is trading 4.49% down in pre-market as biotech ETF XBI falls 3.65% pre-market

Scholar Rock is trading at $38.11, down 4.49%, with biotech-sector pressure the more likely context; no clear company-specific catalyst surfaced for October 19. - The supplied alert reports biotech ETF XBI down 3.65% pre-market amid broader risk-off sentiment. - The October 16 employee inducement grants were routine awards, not a material company development. - ISEMBYLD’s FDA approval was announced in September, not October 19, and does not explain this morning’s decline.